These results show that RUNX3 leads to cetuximab-dependent DNA damage and repair as a cell death regulator; thus, RUNX3 expression (RUNX3 activation) is likely required for effective cetuximab action in response to DNA damage and repair in EGFR-overexpressing NSCLC cells. The gene discussed is RUNX3; the disease is non-small cell lung carcinoma.